Please assess the completion status of the following clinical trial:

Trial Title: Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 18 - 75, inclusive~* Diagnosed with type 2 diabetes~* Hemoglobin A1c value greater than or equal to 8.0%~* Antidiabetic treatments may include sulfonylurea agents (non-sulfonylurea agents must be withdrawn)~* Overweight, obese (body mass index 25-45 kg/m2)~Exclusion Criteria:~* Change of dose of lipid or blood pressure lowering therapy within past three months~* Previous treatment with colesevelam for hyperlipidemia~* Serum triglyceride greater than 500 mg/dL~* Serum low density lipoprotein-cholesterol less than 60 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): colesevelam 3.8g administered daily for 12 weeks
- 2 (Type: PLACEBO_COMPARATOR): Colesevelam matching placebo for 12 weeks
- 3 (Type: ACTIVE_COMPARATOR): open-label Insulin Glargine for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).